Tredan O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with
rising CA125 and no evidence of clinical or RECIST progression: A GINECO
randomized phase II trial (REGOVAR). Gynecol Oncol 2021 Oct 22. pii: S0090-8258(21)01402.
PMID: 34696892